Learning objectives
To summarize the physicochemical properties of ferumoxytol and to discuss its use as a contrast agent (CA) in macrophage-targeted Magnetic Resonance (MR) Neuroimaging (MRN) that display both the tumor vasculature and inflammation of the CNS malignancies..
Background
Neuroimaging is the use of various non/invasive techniques to evaluate the structural and functional properties of the central nervous system (CNS) in healthy individuals and patients [1]. MRI has become an effective non-invasive technique of structural imaging, used in the diagnosis and classification of brain tumors and the evaluation of treatment response [2-4].
Contrast agents (CAs) which can be used to increase the contrast of brain structure in MRN may be categorized by their magnetic and chemical properties, administration method, effect on MR image and...
Findings and procedure details
For this review study, using the keywords ‘MRI, Ferumoxytol, brain, macrophage-targeted’, ferumoxytol based macrophage–targeted MRI-CA primary research studies on human and animal brain tumor diagnosis and brain arteriovenous malformation s(bAVM) were searched for publications dating between 2005 and 2018 in the Web of Science database, described and listed in Figures 4&5.
Macrophages(M), the circulating white blood cells, are involved in the detection and elimination of microorganisms, nanoparticles, dead cells and abnormal tissue [12,13] (Figure 1). The duality of macrophage-associated response, which is essential for immunity...
Conclusion
Ferumoxytol is a MRI-CA compound of safe administration to patients with renal impairment. Ferumoxytol has the potential to display the tumor vascular system, inflammation in CNS malignancies, disease prevalence, time course of inflammation, presence of rupture, etc., and appears as a promising tool that requires further research.
Personal information and conflict of interest
A. Arat; Istanbul, ATASEHIR/TR - Author at Yeditepe University H. C. Sudor; Istanbul/TR - Author at Yeditepe University A. Goz; Istanbul/TR - Author at Yeditepe University S. Özbal; Istanbul/TR - Author at Yeditepe University I. Hasdemir; Istanbul/TR - Author at Yeditepe University A. Yetkin; Istanbul/TR - Author at Yeditepe University A. Hamamci; Istanbul/TR - Author at Yeditepe University S. F. Utku; Istanbul/TR - Author at Yeditepe University G. Ertas; Istanbul/TR - Author at Yeditepe University
References
[1] Sudor HC, et al. European Congress of Radiology 2019, e-Poster no C-3338.
[2] Gahramanov S, et al. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79(2), 514.
[3] Nasseri M, et al. Neuro Oncol. 2014, 16(8):1146.
[4] Brammer, M. Dialogues Clin Neurosci. 2009, 11(4), 389.
[5] Gahramanov S, et al. CNS Oncol. 2014, 3(6):389.
[6] Xiao, YD, et al. International Journal of Molecular Medicine, 2016, 38(5), 1319.
[7] Mukherjee, S,et al. Theranostics 2019, 9(25): 7730.
[8] Shimizu, K, et al. Neurol Med Chir, 2019, 59:257....